See more : SVF Investment Corp. (SVFAW) Income Statement Analysis – Financial Results
Complete financial analysis of Medicure Inc. (MCUJF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicure Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tribal Rides International Corp. (XNDA) Income Statement Analysis – Financial Results
- ASIRO Inc. (7378.T) Income Statement Analysis – Financial Results
- ICL Group Ltd (ICL) Income Statement Analysis – Financial Results
- SIM Acquisition Corp. I Warrant (SIMAW) Income Statement Analysis – Financial Results
- Grown Up Group Investment Holdings Limited (1842.HK) Income Statement Analysis – Financial Results
Medicure Inc. (MCUJF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medicure.com
About Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 21.69M | 23.07M | 21.74M | 11.61M | 20.17M | 29.11M | 27.13M | 37.78M | 22.08M | 5.05M | 2.60M | 4.80M | 3.63M | 3.32M | 4.79M | 2.25M | 5.94M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
Cost of Revenue | 7.71M | 6.99M | 9.03M | 6.48M | 7.27M | 4.15M | 3.46M | 9.77M | 2.26M | 868.12K | 665.90K | 1.07M | 673.52K | 571.69K | 377.08K | 605.62K | 387.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 13.99M | 16.08M | 12.71M | 5.13M | 12.90M | 24.96M | 23.67M | 28.01M | 19.82M | 4.18M | 1.94M | 3.73M | 2.95M | 2.75M | 4.42M | 1.64M | 5.56M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
Gross Profit Ratio | 64.48% | 69.69% | 58.46% | 44.19% | 63.95% | 85.74% | 87.23% | 74.14% | 89.77% | 82.81% | 74.42% | 77.71% | 81.44% | 82.77% | 92.13% | 73.05% | 93.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 2.41M | 2.75M | 1.80M | 3.30M | 4.35M | 6.68M | 5.15M | 5.09M | 4.87M | 688.67K | 1.70M | 1.04M | 204.69K | 393.39K | 22.71K | 28.66M | 23.34M | 10.22M | 13.56M | 4.28M | 3.12M | 3.05M | 2.48M |
General & Administrative | 4.13M | 4.19M | 2.70M | 4.58M | 3.40M | 19.50M | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 8.31M | 7.94M | 10.31M | 5.36M | 13.40M | 15.58M | 11.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 12.44M | 12.13M | 13.01M | 9.94M | 16.79M | 19.50M | 14.87M | 16.23M | 10.24M | 3.33M | 2.32M | 2.67M | 2.82M | 4.47M | 9.26M | 12.07M | 11.05M | 2.86M | 2.26M | 2.11M | 1.28M | 949.57K | 879.91K |
Other Expenses | -854.00K | 346.00K | 1.83M | 0.00 | -3.62M | -1.47M | 82.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 898.93K | 612.52K | 372.80K | 2.65M | 2.29M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 12.58K |
Operating Expenses | 13.99M | 14.88M | 14.81M | 13.24M | 21.14M | 26.18M | 20.02M | 21.33M | 15.10M | 4.02M | 4.02M | 3.72M | 3.92M | 5.48M | 9.65M | 43.39M | 36.67M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
Cost & Expenses | 22.55M | 21.87M | 23.84M | 19.72M | 28.42M | 30.34M | 23.48M | 31.10M | 17.36M | 4.89M | 4.69M | 4.79M | 4.60M | 6.05M | 10.03M | 43.99M | 37.06M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
Interest Income | 75.00K | 10.00K | 78.00K | 43.00K | 886.00K | 1.11M | 0.00 | 0.00 | 0.00 | 41.00 | 152.00 | 775.00 | 473.00 | 4.91K | 255.71K | 1.15M | 1.59M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 183.91K |
Interest Expense | 10.00K | 0.00 | 38.00K | 49.00K | 22.00K | 53.68K | 90.00K | 208.64K | 367.27K | 415.84K | 418.07K | 553.73K | 3.12M | 3.28M | 4.94M | 3.83M | 1.96M | 400.87K | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 2.17M | 2.06M | 3.15M | 2.77M | 1.92M | 299.18K | 97.79K | 1.43M | 690.93K | 561.27K | 536.98K | 877.55K | 898.93K | 919.21K | 938.73K | 2.98M | 2.50M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 17.45K |
EBITDA | 1.29M | 2.87M | 2.42M | -4.02M | -8.81M | -927.00K | 10.35M | 6.39M | 5.41M | 1.86M | -957.03K | -1.49M | -67.62K | -2.29M | -1.33M | -4.30M | -38.76M | -28.62M | -12.78M | -15.43M | -5.95M | -4.16M | -3.81M |
EBITDA Ratio | 5.96% | 14.59% | 11.82% | -38.88% | -43.65% | -4.60% | 43.63% | 17.98% | 7.34% | -12.35% | -62.33% | 18.50% | -1.86% | -69.15% | -18.88% | -1,147.53% | -477.65% | -4,196.11% | -3,345.27% | -1,335.26% | -1,724.36% | -2,074.13% | -2,365.94% |
Operating Income | -854.00K | 1.31M | -574.00K | -7.29M | -10.73M | -1.23M | 3.65M | 6.68M | 4.72M | 164.42K | -2.09M | 10.09K | -1.25M | -3.50M | -6.99M | -41.74M | -31.12M | -12.89M | -15.42M | -5.99M | -4.19M | -3.88M | -3.23M |
Operating Income Ratio | -3.94% | 5.68% | -2.64% | -62.76% | -53.18% | -4.21% | 13.46% | 17.69% | 21.38% | 3.26% | -80.17% | 0.21% | -34.38% | -105.66% | -145.88% | -1,857.66% | -523.41% | -4,298.81% | -3,357.87% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
Total Other Income/Expenses | -43.00K | 192.00K | -185.00K | 1.70M | -11.40M | 6.05M | -1.22M | -2.89M | -3.43M | 1.89M | 152.42K | -487.79K | 23.38M | -1.01M | -2.03M | 6.99M | 10.41M | 18.03M | -200.44K | -1.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax | -897.00K | 1.39M | -759.00K | -6.85M | -19.64M | 4.82M | 2.44M | 28.46M | 1.29M | -1.64M | -2.57M | 23.39M | -2.01M | -2.26M | -8.63M | -54.72M | -31.34M | -13.09M | -15.42M | 0.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax Ratio | -4.13% | 6.00% | -3.49% | -58.96% | -97.36% | 16.57% | 8.98% | 75.33% | 5.84% | -32.45% | -98.91% | 487.53% | -55.51% | -68.07% | -180.01% | -2,435.16% | -527.12% | -4,365.68% | -3,357.87% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 25.00K | 20.00K | -32.00K | 49.00K | 145.00K | 896.88K | -9.06M | 802.83K | -379.00K | 38.20K | -3.01K | -23.93M | -2.07M | -959.99K | 6.53M | 24.81M | -1.15M | -478.47K | -553.34K | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | -922.00K | 1.37M | -727.00K | -6.89M | -19.79M | 3.93M | 43.42M | 27.66M | 1.67M | -1.64M | -2.57M | 23.39M | -2.01M | -5.53M | -13.32M | -57.40M | -31.70M | -12.61M | -14.87M | -5.99M | -4.19M | -3.88M | -3.23M |
Net Income Ratio | -4.25% | 5.92% | -3.34% | -59.38% | -98.08% | 13.49% | 160.03% | 73.21% | 7.56% | -32.45% | -98.91% | 487.53% | -55.51% | -166.79% | -277.85% | -2,554.48% | -533.30% | -4,206.05% | -3,237.37% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
EPS | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.25 | 2.78 | 1.80 | 0.12 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.69 | -2.10 | -3.00 |
EPS Diluted | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.24 | 2.39 | 1.56 | 0.11 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.67 | -2.10 | -3.00 |
Weighted Avg Shares Out | 10.24M | 10.25M | 10.25M | 10.69M | 15.00M | 15.79M | 15.64M | 15.00M | 13.46M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.47M | 1.85M | 1.08M |
Weighted Avg Shares Out (Dil) | 10.44M | 10.44M | 10.25M | 10.69M | 15.00M | 16.56M | 18.14M | 17.32M | 15.77M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.50M | 1.85M | 1.08M |
Medicure Reports Financial Results For Quarter Ended September 30, 2024
Medicure to Present Financial Results on November 26, 2024 Call at 8:30 AM ET for Quarter Ended September 30, 2024 and Announces Resignation of Board Member
Medicure Announces Positive Settlement of Product Development and Supply Contracts
Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property
Medicure Reports Financial Results for Quarter Ended June 30, 2024
Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes
Source: https://incomestatements.info
Category: Stock Reports